Reactivation of ontogenic pathways in metastatic tumors: an exploratory bioinformatics analysis
Keywords:
neoplasias; neoplasia metastasis; organogenesisAbstract
Introduction: Metastasis remains one of cancer’s most adaptive and enigmatic processes. Emerging evidence suggests that metastatic tumor cells may reactivate ontogenic pathways as a strategy for colonization. This study presents an integrative perspective between genomics and developmental biology, exploring potential functional parallels between tumor progression and embryogenesis.
Objectives: To identify genes altered in metastatic tumors that are also involved in embryonic development, and to assess whether these mutational patterns reflect an adaptive logic based on the reactivation of ancestral ontogenic programs.
Methods: This is a cross-sectional observational and exploratory study using bioinformatic analysis of publicly available genomic data retrieved from the cBioPortal platform. Two groups were compared: samples with alterations in key index genes (e.g., TP53, PIK3CA, CTNNB1) versus unaltered samples. Analyses included frequency plots, oncoprints, mutational co-occurrence networks, and curated tables linking genetic alterations to ontogenic functions.
Results: Genes frequently mutated in metastatic samples —including ZFHX4, CSMD1, MYC, TWIST1, NANOG— are also implicated in pluripotency, cell migration, differentiation, and epigenetic reprogramming during embryogenesis. Co-occurrence networks revealed functional nuclei potentially resembling modular ontogenic architectures.
Conclusions: Findings suggest that metastasis may involve the reactivation of ontogenic programs as an adaptive cellular strategy. This perspective offers a reconceptualization of cancer as a biological narrative, wherein pathological behavior reorganizes ancestral structural logic.
Downloads
References
1. National Cancer Institute. Estadísticas del cáncer [Internet]. EE. UU.: NCI; 2025. [acceso: 25/07/2025]. Disponible en: https://www.cancer.gov/espanol/Cancer/naturaleza/estadisticas
2. Quevedo Lorenzo I, Yáñez Crombet AC, Gaínza González BA, Pérez Sariol I, Sánchez Cardona W. Mortalidad por tumores malignos [Internet]. Multimed. 2024. [acceso: 14/01/2025]; 28: e2849. Disponible en: http://scielo.sld.cu//scielo.php?script=sci_abstract&pid=S1028-48182024000100005
3. Thomas F, De Gregori J, Marusyk A, Dujon AM, Ujvari B, Capp JP, et al. A new perspective on tumor progression: evolution via selection for function [Internet]. Evol Med Public Health. 2024;12(1):172-7. DOI: 10.1093/emph/eoae021
4. Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis [Internet]. J Hematol Oncol. 2022;15(1):129. DOI: 10.1186/s13045-022-01347-8
5. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal [Internet]. Sci Signal. 2013;6(269):1. DOI: 10.1126/scisignal.2004088
6. Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer[Internet]. Nature. 2017;548(7667):297-303. DOI: 10.1038/nature23306
7. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base [Internet]. JCO Precis Oncol. 2017;2017:1-16. DOI: 10.1200/PO.17.0001
8. Martínez-Jiménez F, Movasati A, Brunner SR, Nguyen L, Priestley P. Pan-cancer whole-genome comparison of primary and metastatic solid tumours [Internet]. Nature. 2023;618(7964):333-41. DOI: 10.1101/2022.06.17.496528
9. Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25 000 patients [Internet]. Cell. 2022;185(3):563-75. DOI: 10.1016/j.cell.2022.01.003
10. Ouissam AJ, Hind C, Sami Aziz B, Said A. Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: rationale and progress [Internet]. Int J Mol Sci. 2024;25(10):4562. DOI: 10.1177/17588359241284911
11. Al Delbany D, Ghosh MS, Krivec N, Huyghebaert A, Regin M, Duong MC, et al. De novo cancer mutations frequently associate with recurrent chromosomal abnormalities during long term human pluripotent stem cell cultures [Internet]. Cells. 2024;13(16):1395. DOI: 10.3390/cells13161395
12. Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives [Internet]. Signal Transduct Target Ther. 2024;9(1):192. DOI: 10.1038/s41392-024-01885-2
13. Kiri S, Ryba T. Cancer, metastasis, and the epigenome [Internet]. Mol Cancer. 2024;23(1):154. DOI: 10.1186/s12943-024-02069-w
14. Balachandran S, Narendran A. The developmental origins of cancer: a review of the genes expressed in embryonic cells with implications for tumorigenesis [Internet]. Genes (Basel). 2023;14(3):604. DOI: 10.3390/genes14030604
15. Carstens JL, Lovisa S. Epithelial-to-mesenchymal transition drives cancer genomic instability [Internet]. J Exp Clin Cancer Res. 2025;44(1):135. DOI: 10.1186/s13046-025-03402-x
16. Den Hollander P, Maddela JJ, Mani SA. Spatial and temporal relationship between Epithelial-Mesenchymal Transition (EMT) and stem cells in cancer [Internet]. Clin Chem. 2024;70(1):190-205. DOI: 10.1093/clinchem/hvad197
17. Tarin D. Understanding cancer: the molecular mechanisms, biology, pathology and clinical implications of malignant neoplasia. Cham: Springer Nature; 2013.
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Armando Ernesto Pérez Cala, Edgar Benítez Sánchez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
